P70313
SS
Gene name |
Nos3 (Ecnos) |
Protein name |
Nitric oxide synthase 3 |
Names |
EC 1.14.13.39 , Constitutive NOS , cNOS , EC-NOS , NOS type III , NOSIII , Nitric oxide synthase, endothelial , Endothelial NOS , eNOS |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:18127 |
EC number |
1.14.13.39: With NADH or NADPH as one donor, and incorporation of one atom of oxygen |
Protein Class |
|
Descriptions
Nitric oxide synthase produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. The primary sequences of the three mammalian nitric oxide synthase (NOS) isoforms differ by the insertion of a 52-55-amino acid loop into the reductase domains of the endothelial (eNOS) and neuronal (nNOS), but not inducible (iNOS). The loop mediates the autoinhibition in eNOS and nNOS. Deletion of the autoinhibitory loop increases the catalytic activity of eNOS.
Autoinhibitory domains (AIDs)
Target domain |
119-480 (NO synthase domain);729-1161 (FAD/NAD-binding domain) |
Relief mechanism |
Partner binding |
Assay |
|
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for P70313
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-P70313-F1 | Predicted | AlphaFoldDB |
53 variants for P70313
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs3388736828 | 30 | G>S | No | EVA | |
| rs250760086 | 48 | T>A | No | EVA | |
| rs215276564 | 50 | P>A | No | EVA | |
| rs3543301863 | 63 | D>V | No | EVA | |
| rs3388738495 | 71 | K>* | No | EVA | |
| rs3395299034 | 81 | D>N | No | EVA | |
| rs3388738438 | 88 | Q>K | No | EVA | |
| rs3388745266 | 109 | Q>H | No | EVA | |
| rs3388736795 | 121 | Q>H | No | EVA | |
| rs3394989104 | 184 | V>G | No | EVA | |
| rs3388752322 | 187 | I>F | No | EVA | |
| rs3388750011 | 225 | S>L | No | EVA | |
| rs3395368345 | 237 | R>* | No | EVA | |
| rs1134103597 | 265 | A>T | No | EVA | |
| rs582796163 | 267 | V>M | No | EVA | |
| rs32018659 | 298 | P>S | No | EVA | |
| rs3395368329 | 354 | G>D | No | EVA | |
| rs3388747692 | 365 | D>G | No | EVA | |
| rs3395447974 | 374 | I>V | No | EVA | |
| rs3388738456 | 406 | L>* | No | EVA | |
| rs3411224999 | 416 | I>T | No | EVA | |
| rs3388747226 | 439 | G>D | No | EVA | |
| rs3388733329 | 445 | A>P | No | EVA | |
| rs3388720675 | 492 | K>R | No | EVA | |
| rs3388743693 | 519 | A>V | No | EVA | |
| rs224167230 | 529 | R>Q | No | EVA | |
| rs3388733298 | 545 | F>L | No | EVA | |
| rs3388740771 | 548 | R>W | No | EVA | |
| rs3388736789 | 579 | P>R | No | EVA | |
| rs3388752350 | 589 | L>H | No | EVA | |
| rs3388752405 | 598 | S>G | No | EVA | |
| rs3388736815 | 634 | N>K | No | EVA | |
| rs3543295297 | 720 | R>Q | No | EVA | |
| rs3395299987 | 741 | E>D | No | EVA | |
| rs3395117223 | 741 | E>Q | No | EVA | |
| rs3395252214 | 741 | E>V | No | EVA | |
| rs3388743630 | 742 | S>N | No | EVA | |
| rs3388740744 | 753 | H>Y | No | EVA | |
| rs3388738493 | 766 | E>K | No | EVA | |
| rs232469190 | 793 | Q>H | No | EVA | |
| rs3413025486 | 889 | L>I | No | EVA | |
| rs3388747680 | 895 | D>G | No | EVA | |
| rs3395330288 | 900 | E>G | No | EVA | |
| rs3543299283 | 927 | I>L | No | EVA | |
| rs3388752402 | 1001 | P>S | No | EVA | |
| rs3413112127 | 1076 | F>L | No | EVA | |
| rs3388747290 | 1076 | F>L | No | EVA | |
| rs3388746258 | 1081 | G>D | No | EVA | |
| rs3388746241 | 1094 | E>D | No | EVA | |
| rs3388747699 | 1129 | I>S | No | EVA | |
| rs3388730728 | 1169 | T>A | No | EVA | |
| rs3388753548 | 1177 | F>L | No | EVA | |
| rs215583835 | 1196 | G>A | No | EVA |
No associated diseases with P70313
17 regional properties for P70313
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | Flavodoxin-like | 520 - 533 | IPR001094-1 |
| domain | Flavodoxin-like | 567 - 578 | IPR001094-2 |
| domain | Flavodoxin-like | 643 - 653 | IPR001094-3 |
| domain | Flavodoxin-like | 667 - 686 | IPR001094-4 |
| domain | Oxidoreductase FAD/NAD(P)-binding | 1010 - 1122 | IPR001433 |
| domain | Flavoprotein pyridine nucleotide cytochrome reductase | 792 - 802 | IPR001709-1 |
| domain | Flavoprotein pyridine nucleotide cytochrome reductase | 937 - 944 | IPR001709-2 |
| domain | Flavoprotein pyridine nucleotide cytochrome reductase | 973 - 982 | IPR001709-3 |
| domain | Flavoprotein pyridine nucleotide cytochrome reductase | 1009 - 1028 | IPR001709-4 |
| domain | Flavoprotein pyridine nucleotide cytochrome reductase | 1039 - 1048 | IPR001709-5 |
| domain | Flavoprotein pyridine nucleotide cytochrome reductase | 1052 - 1063 | IPR001709-6 |
| domain | Flavoprotein pyridine nucleotide cytochrome reductase | 1084 - 1100 | IPR001709-7 |
| domain | Flavoprotein pyridine nucleotide cytochrome reductase | 1109 - 1117 | IPR001709-8 |
| domain | Sulfite reductase [NADPH] flavoprotein alpha-component-like, FAD-binding | 751 - 978 | IPR003097 |
| domain | Nitric oxide synthase, N-terminal | 119 - 480 | IPR004030 |
| domain | Flavodoxin/nitric oxide synthase | 519 - 702 | IPR008254 |
| domain | FAD-binding domain, ferredoxin reductase-type | 755 - 1001 | IPR017927 |
Functions
| Description | ||
|---|---|---|
| EC Number | 1.14.13.39 | With NADH or NADPH as one donor, and incorporation of one atom of oxygen |
| Subcellular Localization |
|
|
| PANTHER Family | ||
| PANTHER Subfamily | ||
| PANTHER Protein Class | ||
| PANTHER Pathway Category | No pathway information available | |
9 GO annotations of cellular component
| Name | Definition |
|---|---|
| apical part of cell | The region of a polarized cell that forms a tip or is distal to a base. For example, in a polarized epithelial cell, the apical region has an exposed surface and lies opposite to the basal lamina that separates the epithelium from other tissue. |
| caveola | A membrane raft that forms small pit, depression, or invagination that communicates with the outside of a cell and extends inward, indenting the cytoplasm and the cell membrane. Examples include flask-shaped invaginations of the plasma membrane in adipocytes associated with caveolin proteins, and minute pits or incuppings of the cell membrane formed during pinocytosis. Caveolae may be pinched off to form free vesicles within the cytoplasm. |
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| cytoskeleton | A cellular structure that forms the internal framework of eukaryotic and prokaryotic cells. The cytoskeleton includes intermediate filaments, microfilaments, microtubules, the microtrabecular lattice, and other structures characterized by a polymeric filamentous nature and long-range order within the cell. The various elements of the cytoskeleton not only serve in the maintenance of cellular shape but also have roles in other cellular functions, including cellular movement, cell division, endocytosis, and movement of organelles. |
| cytosol | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. |
| Golgi apparatus | A membrane-bound cytoplasmic organelle of the endomembrane system that further processes the core oligosaccharides (e.g. N-glycans) added to proteins in the endoplasmic reticulum and packages them into membrane-bound vesicles. The Golgi apparatus operates at the intersection of the secretory, lysosomal, and endocytic pathways. |
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
| plasma membrane | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. |
| sarcolemma | The outer membrane of a muscle cell, consisting of the plasma membrane, a covering basement membrane (about 100 nm thick and sometimes common to more than one fiber), and the associated loose network of collagen fibers. |
16 GO annotations of molecular function
| Name | Definition |
|---|---|
| actin binding | Binding to monomeric or multimeric forms of actin, including actin filaments. |
| actin monomer binding | Binding to monomeric actin, also known as G-actin. |
| arginine binding | Binding to 2-amino-5-(carbamimidamido)pentanoic acid. |
| beta-catenin binding | Binding to a catenin beta subunit. |
| cadherin binding | Binding to cadherin, a type I membrane protein involved in cell adhesion. |
| calmodulin binding | Binding to calmodulin, a calcium-binding protein with many roles, both in the calcium-bound and calcium-free states. |
| flavin adenine dinucleotide binding | Binding to FAD, flavin-adenine dinucleotide, the coenzyme or the prosthetic group of various flavoprotein oxidoreductase enzymes, in either the oxidized form, FAD, or the reduced form, FADH2. |
| FMN binding | Binding to flavin mono nucleotide. Flavin mono nucleotide (FMN) is the coenzyme or the prosthetic group of various flavoprotein oxidoreductase enzymes. |
| heme binding | Binding to a heme, a compound composed of iron complexed in a porphyrin (tetrapyrrole) ring. |
| Hsp90 protein binding | Binding to Hsp90 proteins, any of a group of heat shock proteins around 90kDa in size. |
| metal ion binding | Binding to a metal ion. |
| NADP binding | Binding to nicotinamide-adenine dinucleotide phosphate, a coenzyme involved in many redox and biosynthetic reactions; binding may be to either the oxidized form, NADP+, or the reduced form, NADPH. |
| nitric-oxide synthase activity | Catalysis of the reaction |
| nitric-oxide synthase binding | Binding to nitric-oxide synthase. |
| scaffold protein binding | Binding to a scaffold protein. Scaffold proteins are crucial regulators of many key signaling pathways. Although not strictly defined in function, they are known to interact and/or bind with multiple members of a signaling pathway, tethering them into complexes. |
| tetrahydrobiopterin binding | Binding to a tetrahydrobiopterin, 5,6,7,8-tetrahydrobiopterin or a derivative thereof; tetrahydrobiopterins are enzyme cofactors that carry electrons in redox reactions. |
42 GO annotations of biological process
| Name | Definition |
|---|---|
| angiogenesis | Blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels. |
| aortic valve morphogenesis | The process in which the structure of the aortic valve is generated and organized. |
| arginine catabolic process | The chemical reactions and pathways resulting in the breakdown of arginine, 2-amino-5-(carbamimidamido)pentanoic acid. |
| blood vessel diameter maintenance | Any process that modulates the diameter of blood vessels. |
| blood vessel remodeling | The reorganization or renovation of existing blood vessels. |
| calcium ion transport | The directed movement of calcium (Ca) ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. |
| cellular response to mechanical stimulus | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a mechanical stimulus. |
| cellular response to transforming growth factor beta stimulus | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a transforming growth factor beta stimulus. |
| endocardial cushion morphogenesis | The process in which the anatomical structure of the endocardial cushion is generated and organized. The endocardial cushion is a specialized region of mesenchymal cells that will give rise to the heart septa and valves. |
| endothelial cell migration | The orderly movement of an endothelial cell into the extracellular matrix to form an endothelium. |
| establishment of localization in cell | Any process, occuring in a cell, that localizes a substance or cellular component. This may occur via movement, tethering or selective degradation. |
| homeostasis of number of cells within a tissue | Any biological process involved in the maintenance of the steady-state number of cells within a population of cells in a tissue. |
| in utero embryonic development | The process whose specific outcome is the progression of the embryo in the uterus over time, from formation of the zygote in the oviduct, to birth. An example of this process is found in Mus musculus. |
| lipopolysaccharide-mediated signaling pathway | The series of molecular signals initiated by the binding of a lipopolysaccharide (LPS) to a receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. Lipopolysaccharides are major components of the outer membrane of Gram-negative bacteria, making them prime targets for recognition by the immune system. |
| lung development | The process whose specific outcome is the progression of the lung over time, from its formation to the mature structure. In all air-breathing vertebrates the lungs are developed from the ventral wall of the oesophagus as a pouch which divides into two sacs. In amphibians and many reptiles the lungs retain very nearly this primitive sac-like character, but in the higher forms the connection with the esophagus becomes elongated into the windpipe and the inner walls of the sacs become more and more divided, until, in the mammals, the air spaces become minutely divided into tubes ending in small air cells, in the walls of which the blood circulates in a fine network of capillaries. In mammals the lungs are more or less divided into lobes, and each lung occupies a separate cavity in the thorax. |
| negative regulation of biomineral tissue development | Any process that stops, prevents, or reduces the frequency, rate or extent of biomineral tissue development, the formation of hard tissues that consist mainly of inorganic compounds. |
| negative regulation of blood pressure | Any process in which the force of blood traveling through the circulatory system is decreased. |
| negative regulation of calcium ion transport | Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of calcium ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. |
| negative regulation of cell population proliferation | Any process that stops, prevents or reduces the rate or extent of cell proliferation. |
| negative regulation of muscle hyperplasia | Any process that stops, prevents, or reduces the frequency, rate, or extent of muscle hyperplasia. |
| negative regulation of potassium ion transport | Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. |
| negative regulation of smooth muscle cell proliferation | Any process that stops, prevents or reduces the rate or extent of smooth muscle cell proliferation. |
| nitric oxide biosynthetic process | The chemical reactions and pathways resulting in the formation of nitric oxide, nitrogen monoxide (NO), a colorless gas only slightly soluble in water. |
| nitric oxide mediated signal transduction | Any intracellular signal transduction in which the signal is passed on within the cell via nitric oxide (NO). Includes synthesis of nitric oxide, receptors/sensors for nitric oxide (such as soluble guanylyl cyclase/sGC) and downstream effectors that further transmit the signal within the cell. Nitric oxide transmits its downstream effects through either cyclic GMP (cGMP)-dependent or independent mechanisms. |
| ovulation from ovarian follicle | The process leading to the rupture of the follicle, releasing the centrally located oocyte into the oviduct. An example of this is found in Mus musculus. |
| positive regulation of angiogenesis | Any process that activates or increases angiogenesis. |
| positive regulation of apoptotic process | Any process that activates or increases the frequency, rate or extent of cell death by apoptotic process. |
| positive regulation of blood vessel endothelial cell migration | Any process that activates or increases the frequency, rate or extent of the migration of the endothelial cells of blood vessels. |
| positive regulation of gene expression | Any process that increases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product (protein or RNA). |
| potassium ion transport | The directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. |
| pulmonary valve morphogenesis | The process in which the structure of the pulmonary valve is generated and organized. |
| regulation of nervous system process | Any process that modulates the frequency, rate or extent of a neurophysiological process, an organ system process carried out by any of the organs or tissues of the nervous system. |
| regulation of sodium ion transport | Any process that modulates the frequency, rate or extent of the directed movement of sodium ions (Na+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. |
| regulation of systemic arterial blood pressure by endothelin | The process in which endothelin modulates the force with which blood passes through the circulatory system. Endothelin is a hormone that is released by the endothelium, and it is a vasoconstrictor. |
| regulation of the force of heart contraction by chemical signal | The regulation of the force of heart muscle contraction mediated by chemical signaling, hormonal, autocrine or paracrine. |
| removal of superoxide radicals | Any process, acting at the cellular level, involved in removing superoxide radicals (O2-) from a cell or organism, e.g. by conversion to dioxygen (O2) and hydrogen peroxide (H2O2). |
| response to estradiol | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of stimulus by estradiol, a C18 steroid hormone hydroxylated at C3 and C17 that acts as a potent estrogen. |
| response to fluid shear stress | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a fluid shear stress stimulus. Fluid shear stress is the force acting on an object in a system where the fluid is moving across a solid surface. |
| response to hormone | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hormone stimulus. |
| response to lipopolysaccharide | Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipopolysaccharide stimulus; lipopolysaccharide is a major component of the cell wall of gram-negative bacteria. |
| smooth muscle hyperplasia | A process, occurring in smooth muscle, in which there is an increase in cell number by cell division, often leading to an increase in the size of an organ. |
| ventricular septum morphogenesis | The developmental process in which a ventricular septum is generated and organized. A ventricular septum is an anatomical structure that separates the lower chambers (ventricles) of the heart from one another. |
12 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| P29473 | NOS3 | Nitric oxide synthase, endothelial | Bos taurus (Bovine) | EV |
| Q9TUX8 | NOS3 | Nitric oxide synthase 3 | Canis lupus familiaris (Dog) (Canis familiaris) | SS |
| Q9UBK8 | MTRR | Methionine synthase reductase | Homo sapiens (Human) | PR |
| P29475 | NOS1 | Nitric oxide synthase, brain | Homo sapiens (Human) | SS |
| P29474 | NOS3 | Nitric oxide synthase, endothelial | Homo sapiens (Human) | SS |
| A2AI05 | Ndor1 | NADPH-dependent diflavin oxidoreductase 1 | Mus musculus (Mouse) | PR |
| Q8C1A3 | Mtrr | Methionine synthase reductase | Mus musculus (Mouse) | PR |
| Q28969 | NOS3 | Nitric oxide synthase 3 | Sus scrofa (Pig) | SS |
| Q498R1 | Mtrr | Methionine synthase reductase | Rattus norvegicus (Rat) | PR |
| P29476 | Nos1 | Nitric oxide synthase, brain | Rattus norvegicus (Rat) | SS |
| Q62600 | Nos3 | Nitric oxide synthase 3 | Rattus norvegicus (Rat) | SS |
| Q9FKW6 | LFNR1 | Ferredoxin--NADP reductase, leaf isozyme 1, chloroplastic | Arabidopsis thaliana (Mouse-ear cress) | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MGNLKSVGQE | PGPPCGLGLG | LGLGLCGKQG | PASPAPEPSQ | APAPPSPTRP | APDHSPPLTR |
| 70 | 80 | 90 | 100 | 110 | 120 |
| PPDGPRFPRV | KNWEVGSITY | DTLSAQAQQD | GPCTSRRCLG | SLVFPRKLQS | RPTQGPSPTE |
| 130 | 140 | 150 | 160 | 170 | 180 |
| QLLGQARDFI | NQYYNSIKRS | GSQAHEQRLQ | EVEAEVAATG | TYQLRESELV | FGAKQAWRNA |
| 190 | 200 | 210 | 220 | 230 | 240 |
| PRCVGRIQWG | KLQVFDARDC | RTAQEMFTYI | CNHIKYATNR | GNLRSAITVF | PQRCPGRGDF |
| 250 | 260 | 270 | 280 | 290 | 300 |
| RIWNSQLIRY | AGYRQQDGSV | RGDPANVEIT | ELCIQHGWTP | GNGRFDVLPL | LLQAPDEPPE |
| 310 | 320 | 330 | 340 | 350 | 360 |
| LFTLPPEMVL | EVPLEHPTLE | WFAALGLRWY | ALPAVSNMLL | EIGGLEFPAA | PFSGWYMSSE |
| 370 | 380 | 390 | 400 | 410 | 420 |
| IGMRDLCDPH | RYNILEDVAV | CMDLDTRTTS | SLWKDKAAVE | INVAVLHSYQ | LAKVTIVDHH |
| 430 | 440 | 450 | 460 | 470 | 480 |
| AATASFMKHL | ENEQKARGGC | PADWAWIVPP | ISGSLTPVFH | QEMVNYFLSP | AFRYQPDPWK |
| 490 | 500 | 510 | 520 | 530 | 540 |
| GSAAKGAGIT | RKKTFKEVAN | AVKISASLMG | TVMAKRVKAT | ILYGSETGRA | QSYAQQLGRL |
| 550 | 560 | 570 | 580 | 590 | 600 |
| FRKAFDPRVL | CMDEYDVVSL | EHEALVLVVT | STFGNGDPPE | NGESFAAALM | EMSGPYNSSP |
| 610 | 620 | 630 | 640 | 650 | 660 |
| RPEQHKSYKI | RFNSVSCSDP | LVSSWRRKRK | ESSNTDSAGA | LGTLRFCVFG | LGSRAYPHFC |
| 670 | 680 | 690 | 700 | 710 | 720 |
| AFARAVDTRL | EELGGERLLQ | LGQGDELCGQ | EEAFRGWAQA | AFQAACETFC | VGEDAKAAAR |
| 730 | 740 | 750 | 760 | 770 | 780 |
| DIFSPKRSWK | RQRYRLSTQA | ESLQLLPGLT | HVHRRKMFQA | TILSVENLQS | SKSTRATILV |
| 790 | 800 | 810 | 820 | 830 | 840 |
| RLDTGGQEGL | QYQPGDHIGV | CPPNRPGLVE | ALLSRVEDPP | PSTEPVAVEQ | LEKGSPGGPP |
| 850 | 860 | 870 | 880 | 890 | 900 |
| PGWVRDPRLP | PCTLRQALTY | FLDITSPPSP | RLLRLLSTLA | EESSEQQELE | ALSQDPRRYE |
| 910 | 920 | 930 | 940 | 950 | 960 |
| EWKWFSCPTL | LEVLEQFPSV | ALPAPLILTQ | LPLLQPRYYS | VSSAPSAHPG | EIHLTIAVLA |
| 970 | 980 | 990 | 1000 | 1010 | 1020 |
| YRTQDGLGPL | HYGVCSTWMS | QLKAGDPVPC | FIRGAPSFRL | PPDPNLPCIL | VGPGTGIAPF |
| 1030 | 1040 | 1050 | 1060 | 1070 | 1080 |
| RGFWQDRLHD | IEIKGLQPAP | MTLVFGCRCS | QLDHLYRDEV | LDAQQRGVFG | QVLTAFSRDP |
| 1090 | 1100 | 1110 | 1120 | 1130 | 1140 |
| GSPKTYVQDL | LRTELAAEVH | RVLCLEQGHM | FVCGDVTMAT | SVLQTVQRIL | ATEGGMELDE |
| 1150 | 1160 | 1170 | 1180 | 1190 | 1200 |
| AGDVIGVLRD | QQRYHEDIFG | LTLRTQEVTS | RIRTQSFSLQ | ERQLRGAVPW | SFDPPGPEIP |
| GS |